Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q3 FY22 results · Oct–Dec 2021
Procter & Gamble Health reported revenue from operations of ₹277.90 crore (up 15.7% from Q3 FY21) and net profit of ₹44.84 crore (down 33.9% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 277.90 | 240.22 | +15.7% | 272.80 | +1.9% |
| Other income | 4.70 | 5.72 | −17.8% | 3.04 | +54.6% |
| Total income | 282.60 | 245.94 | +14.9% | 275.84 | +2.5% |
| Profit before tax | 59.83 | 86.43 | −30.8% | 74.07 | −19.2% |
| Net profit for the period | 44.84 | 67.88 | −33.9% | 55.37 | −19.0% |
| EPS, basic (₹) | 27.00 | 40.90 | −34.0% | 33.40 | −19.2% |
| Net margin (%) | 16.1 | 28.3 | 20.3 |
Standalone
- Filed with BSE
- 10 Feb 2022, 08:40 IST
- Board meeting
- 09 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE